Sanofi American Depositary Receipt (SNY)
Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?
Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%
Several stocks with market capitalizations above $100 billion just made notable dividend announcements. These names are among the largest in their respective industries, and despite widely differing performance, continue to make good on their commitments to return more capital to shareholders.
SNY & REGN's Dupixent Wins FDA Nod for Pediatric Use in Urticaria
Sanofi wins FDA nod to expand Dupixent in kids aged 2-11 years, marking the first biologic for young patients with uncontrolled CSU.
SNY's Tzield Gets FDA Nod for Kids, Sarclisa SC BLA Faces Delay
Sanofi wins FDA nod to expand Tzield's use to younger patients, while Sarclisa SC review faces delay with a new decision date set for July 2026.
Sanofi Tops Q1 Earnings Estimates as Dupixent & New Drugs Drive Growth
Sanofi beats Q1 estimates as Dupixent and new drugs fuel double-digit growth, with strong sales and earnings gains supporting its 2026 outlook.
Sanofi Posts Higher Sales Amid Leadership Transition
Sales rose 14% to €10.51 billion at constant currency, boosted by new launches and recent acquisitions.
Sanofi's first quarter earnings edges past estimates ahead of CEO change
French drugmaker Sanofi on Thursday reported first-quarter profit and revenue above market expectations, boosted by resilient demand for its blockbuster asthma and eczema drug Dupixent.
What To Expect From Sanofi In Q1 2026
On April 23, Sanofi will report its results for the first quarter of 2026. As a reminder, its revenue grew 23.1% year-over-year to $13.53 billion in Q4 last year. Meanwhile, Sanofi's non-GAAP P/E ratio [FWD] is 9.66x, which, in my view, clearly indicates that it is trading at a discount.
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria
Sanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the first targeted option in the EU.
SNY's Lunsekimig Succeeds in Asthma & CRSwNP Studies, Fails in Eczema
Sanofi posts strong mid-stage results for lunsekimig in asthma and CRSwNP but a setback in atopic dermatitis clouds the broader clinical picture.
Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease
SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment
Kali Therapeutics said on Monday it has entered into a licensing agreement with French drugmaker Sanofi to develop the privately held firm's experimental treatment for several autoimmune diseases.
